Goldman Adds Cigna To Conviction Buy List, Expects DoJ Announcement To Refocus Investors On Standalone Merits


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Goldman Sachs has added CIGNA Corporation

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

(NYSE: CI) to its Conviction Buy List with 18 percent upside to the stock, saying that the antitrust regulators intention to block Cigna's proposed merger with Anthem Inc (NYSE: ANTM) would refocus investors on Cigna's standalone traits.

"While we do not take a view on the whether the transaction will complete, we expect the announcement will likely cause investors to refocus on CI's strong standalone fundamentals driven by a diversified business mix producing forecast mid-to-high single-digit revenue growth and 9–12 percent EPS growth," analyst Matthew Borsch wrote in a note.

If the proposed merger fails to take off, Borsch still thinks Cigna could deploy at least $9 billion, if it brought its debt leverage up to the level of UnitedHealth Group Inc (NYSE: UNH)/Anthem/Aetna Inc (NYSE: AET) (i.e., mid-40 percent debt/cap).


FREE REPORT: How To Learn Options Trading Fast

In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, ​a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.


"This would be equivalent to more than one-quarter of CI's market cap and we estimate could be ~26 percent accretive to our 2018 EPS if used for share repurchase," Borsch highlighted.

The analyst expects EPS of $9.45 for 2016, $10.45 for 2017 and $11.75 for 2018.

Further, the analyst noted that Cigna's margins would be shielded from a "late-cycle" upturn in medical cost/utilization trend given its non-risk (ASO) weighted enrollment.

Borsche cut the price target to $165 from $170 as the analyst removed the M&A component from his model.

Shares of Cigna closed Thursday's regular trading at $140.32 and were seen up 2.14 percent just minutes after Friday's open, trading at $143.32.

Full ratings data available on Benzinga Pro.

Did you like this article? Could it have been improved? Please email feedback@benzinga.com with the story link to let us know!


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: Analyst ColorLong IdeasNewsHealth CarePrice TargetReiterationM&AAnalyst RatingsMoversTrading IdeasGeneralGoldman Sachs